Advertisement
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NZD/USD

    0.5955
    +0.0005 (+0.08%)
     
  • NZD/EUR

    0.5567
    +0.0026 (+0.48%)
     
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • OIL

    83.69
    +0.12 (+0.14%)
     
  • GOLD

    2,352.10
    +9.60 (+0.41%)
     
  • NASDAQ

    17,696.31
    +265.81 (+1.53%)
     
  • FTSE

    8,138.91
    +60.05 (+0.74%)
     
  • Dow Jones

    38,278.57
    +192.77 (+0.51%)
     
  • DAX

    18,175.65
    +258.37 (+1.44%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • NZD/JPY

    93.4440
    +0.9480 (+1.02%)
     

What May Have Driven Life Science Property Provider Ventas in Q2

What May Have Driven Life Science Property Provider Ventas in Q2

Ventas (VTR) is slated to report its second-quarter results on July 27. Wall Street expects its results to be mixed, with revenue rising 1.6% YoY (year-over-year) to $910.2 million and AFFO (adjusted funds from operations) per share falling 2.9%. The segment is struggling with market oversupply, which is impacting its pricing power, average occupancy rate, and monthly REVPOR (revenue per occupied room).